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Abstract
Purpose: Acute Intermittent Porphyria (AIP) is a rare inborn error of heme biosynthesis 
characterized by life-threatening acute attacks. Few studies have assessed quality of life (QoL) in 
AIP and those that have had small sample sizes and used tools that may not have captured 
important domains.
Methods: Baseline data from the Porphyrias Consortium’s Longitudinal Study were obtained for 
259 patients, including detailed disease and medical history data, and the following PROMIS 
scales: anxiety, depression, pain interference, fatigue, sleep disturbance, physical function, and 
satisfaction with social roles. Relationships between PROMIS scores and clinical and biochemical 
AIP features were explored.
Results: PROMIS scores were significantly worse than the general population across all 
domains, except depression. Each domain discriminated well between asymptomatic and 
symptomatic patients with symptomatic patients having worse scores. Many important clinical 
variables like symptom frequency were significantly associated with domain scores in univariate 
analyses, showing responsiveness of the scales, specifically pain interference and fatigue. 
However, most regression models only explained ~20% of the variability observed in domain 
scores.
Conclusion: Pain interference and fatigue were the most responsive scales in measuring QoL in 
this AIP cohort. Future studies should assess whether these scales capture longitudinal disease 
progression and treatment response.
Keywords
Acute Intermittent Porphyria; Quality of Life; PROMIS; Patient-reported Outcomes
INTRODUCTION
Acute Intermittent Porphyria (AIP), the most common of four acute hepatic porphyrias, is a 
rare, dominantly inherited, disorder of heme biosynthesis. Clinically, it is characterized by 
acute neurovisceral symptoms of severe abdominal pain, nausea, vomiting, muscle 
weakness, and tachycardia that, if untreated, may lead to seizures, hallucinations, and/or 
paralysis1-5. These symptoms generally develop after puberty. Recent studies have shown 
that the true heterozygote prevalence is estimated to be about 1 in 1700 in Caucasians6 but 
the estimated penetrance is very low with 80-90% of mutation carriers never experiencing 
symptoms (latent)3,6-8.
Acute attacks can be triggered by certain factors that can lead to significant elevations of the 
neurotoxic porphyrin precursors, 5-aminolevulinic acid (ALA) and porphobilinogen (PBG). 
Known precipitating factors include hormonal changes, excess alcohol consumption, fasting, 
and medications that induce cytochrome P450 enzymes3,8,9. Stress has been described as a 
possible precipitating factor although the extent to which stress induces acute attacks has not 
been determined9-11. The levels of ALA and PBG are significantly elevated during acute 
attacks and, in some patients, can remain chronically elevated8,12. There is a wide range of 
disease severity ranging from sporadic attacks throughout patients’ lives to recurrent acute 
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attacks (commonly defined as ≥4/year). A small subset of patients, particularly females, can 
experience monthly attacks1,3,8,13. As well, patients may develop symptoms such as chronic 
pain and neuropathy.
The current treatment for acute attacks is intravenous infusions of hemin (Panhematin in the 
US; Normosang in Europe and other countries) which is typically administered once a day 
for four consecutive days10,11,14-16. Some patients with recurrent attacks receive 
prophylactic hemin, ranging from weekly to monthly infusions, to ameliorate symptoms and 
prevent hospitalization17,18.
It is unclear how disease symptoms and severity affect Quality of Life (QoL) in individuals 
with AIP. Previous QoL studies in this population have used the Illness Perception 
Questionnaire, the Hospital Anxiety Depression Scale, and the EuroQoL. These studies have 
shown that symptomatic AIP patients have significantly decreased QoL, an increased 
incidence of anxiety, impaired physical functioning, and that disease negatively impacts their 
employment19-21. However, these studies were limited in that they consisted only of 
descriptive analyses, all used different tools, combined the different types of acute 
porphyria, and sample sizes in each study were relatively small (20-90 patients).
Accurate and standardized QoL information could give healthcare providers an accurate 
assessment of the disease’s impairment on a patients’ QoL so that specific interventions 
could be recommended and developed to enhance the lives of these patients. As well, the 
importance of QoL and patient-reported outcomes (PROs) has become part of Food and 
Drug Administration (FDA) new drug/indication approvals. Thus, it is important that the 
tools to measure QoL be carefully evaluated for different diseases. QoL assessments used in 
previous studies may not have captured all the relevant AIP disease-specific domains nor did 
they discriminate among patients with different disease severities. Therefore, there is a need 
for a reliable and valid QoL questionnaire that encompasses the range of symptoms and 
severities experienced by AIP patients.
The Patient Reported Outcomes Measurement Information System (PROMIS®) initiative of 
the National Institutes of Health was developed to advance PRO22,23. PROMIS consists of a 
network of collaborative researchers who are developing flexible and dynamic PROs 
applicable to patients with a wide range of chronic diseases for use in research and clinical 
practice23-25. The PROMIS tools assess many different domains and although many of the 
scales are considered psychometrically robust and have been validated in the general United 
States (US) population24 and for several diseases26-28, they have not been assessed in many 
rare diseases. In general, given the nature of these diseases, standard statistical analyses for 
assessing QoL are limited due to small sample sizes. Therefore, the goal of this study was to 
assess the PROMIS-57 in a relatively large sample of AIP patients to determine its 
effectiveness as a PRO measure and explore associations with clinical and biochemical 
features of the disease to determine if PROMIS scales capture relevant QoL issues in AIP.
Naik et al. Page 3
Genet Med. Author manuscript; available in PMC 2020 May 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
METHODS
The study (NCT01561157) was performed at nine sites of the Porphyrias Consortium of the 
Rare Diseases Clinical Research Network and conducted in accordance with the Declaration 
of Helsinki. The Institutional Review Boards at the Icahn School of Medicine at Mount 
Sinai, University of Texas Medical Branch, University of California at San Francisco, 
University of Alabama, Wake Forest University, University of Utah, University of 
Washington, University of Miami, and Cleveland Clinic approved the study and informed 
consent was obtained. Study procedures were described previously13. Briefly, all patients 
included had a confirmed diagnosis of AIP with significantly elevated urine PBG (>8 mg/24 
hours or g creatinine, or >2x increase relative to upper limit of normal) and/or a pathogenic 
HMBS mutation and detailed medical histories were taken at baseline. Patients ≥18 years 
old were given the PROMIS-57 Version 1 scale which includes the following domains: 
Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Satisfaction with Social 
Roles, and Pain Interference. Individual PROMIS responses were scored per the established 
protocol29. Patients with Variegate Porphyria and Hereditary Coproporphyria were excluded 
from this study, as their cutaneous symptoms would have additional QoL effects not 
applicable to AIP patients.
Statistical Analyses
PROMIS domain scores were compared to the general population scores (standardized mean 
score of 50 in each domain)29 using one-sample, two-sided T-tests and between self-reported 
asymptomatic (latent) and symptomatic (sporadic, recurrent attacks, or chronic symptoms) 
AIP patients using two-sample, , two-sided T-tests or analysis of variance (ANOVA) as 
appropriate. Higher scores indicate a greater impact on that domain (e.g. higher anxiety 
scores mean greater anxiety but higher physical function scores mean better physical 
function). The impact of disease severity on PROMIS scores was explored using univariate 
and multiple regression analyses. The covariates included baseline clinical and biochemical 
features of AIP, gender, age at symptom onset , number of hospitalizations for acute attacks, 
medical histories of anxiety, chronic nausea, neuropathy, symptom frequency (patients were 
categorized into severity groups based on frequency of acute attacks they have experienced; 
sporadic attacks, recurrent attacks, or chronic symptoms), menopausal status, previous or 
current treatment with hemin, and urine PBG levels. Urine PBG levels were transformed 
into a fold-over-normal variable by dividing the result by the upper reference limit given by 
the performing laboratory to account for differing reporting units. Univariate analyses were 
conducted to determine which covariates should be included in the regression models using 
a threshold p-value of ≤0.2. Models were fit for each of the domain scores. Associations 
between PROMIS scores and genotype were also assessed. Mutations were categorized into 
missense, nonsense, insertions/deletions (Indels), and consensus splice site lesions. Analyses 
were considered exploratory and conducted at the 0.05 significance level using SAS version 
9.4 (SAS, Cary, North Carolina)30.
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RESULTS
Two hundred fifty nine adult patients with AIP were included. Demographics and disease 
characteristics are shown in Table 1. The majority of patients were female (82.2%), white 
(89.2%), and reported experiencing symptoms either currently or in the past (73.9%). 
Disease severity varied; patients reported a wide range of number of life time 
hospitalizations and 45% of symptomatic patients reported having recurrent attacks defined 
as four or more per year.
Distribution of PROMIS Responses
Two hundred thirty-two patients (89.6 %) completed the PROMIS-57 at baseline. The mean 
PROMIS domain scores are shown in Table 2. With the exception of the depression domain, 
each domain had >25% of patients with clinically significant impairment, defined as a ≥1 
standard deviation worse score than that of the general population mean. The pain 
interference domain had 40% of patients with impairment. With the exception of the 
depression domain, AIP patient mean scores across all domains were significantly worse 
than the general population. Comparisons of scores between symptomatic and asymptomatic 
patients showed significantly worse scores in each domain for those who reported symptoms 
(Figure 1).
Univariate Analyses in Symptomatic Patients
PROMIS domain scores were compared between several key clinical features of the disease. 
Females had significantly worse mean scores in the physical function and fatigue domains. It 
should be noted that the sample size for symptomatic men was small and therefore limiting 
(~20) (Supplementary Table 1).
With the exception of pain interference, mean scores of patients with a history of anxiety 
showed significantly worse scores in each domain compared to those with no history of 
anxiety. Patients reporting chronic nausea had significantly worse mean scores in each 
domain except the depression, anxiety, and physical function domains. Patients with a 
history of chronic neuropathy had significantly worse mean scores in pain interference, 
physical function, fatigue, and satisfaction with social roles domains (Supplementary Table 
1). However, only 13 patients had a medical history of neuropathy. Patients who have 
received hemin in the past, likely for more severe disease, had significantly worse scores in 
pain interference, depression, physical function, and satisfaction with social roles domains. 
Symptomatic pre- and postmenopausal women had no significant differences in any of the 
domains.
Patients with greater disease severity as characterized by acute attack frequency (sporadic, 
recurrent, or chronic symptoms) had significantly worse mean scores in all the domains, 
except the anxiety domain (Figure 2). Age at onset only demonstrated a significant 
association with sleep disturbance, and age at enrollment only demonstrated as significant 
association with depression. Number of hospitalizations was significantly associated with 
pain interference, fatigue, and sleep disturbance. PBG level was not significantly associated 
with any domain (Supplementary Table 1). Only four patients reported a medical diagnosis 
Naik et al. Page 5
Genet Med. Author manuscript; available in PMC 2020 May 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of depression at baseline and only seven had fatigue specifically noted in their baseline 
medical history; therefore, these were not considered as potential predictors.
Multivariable Models
Individual models were refined based on the clinical significance of each predictor and p-
values. The final reduced models are shown in Table 3. All final models accounted for >15% 
of the variability in domain scores with the exception of the depression, anxiety, and sleep 
disturbance models which accounted for only 12.8%, 3.4%, and 9.8% respectively.
Significant predictors of pain interference scores were frequency of symptoms (Chronic vs. 
Sporadic β=7.27, p-value=0.007; Recurrent vs. Sporadic β=7.24, p-value=0.0003), a history 
of neuropathy (β= 6.27, p-value=0.05), and a history of nausea (β= 5.24, p-value=0.02). 
This model accounted for 27.4% of the variability observed in the pain interference scores. 
These variables, as well as hemin use, were included in the final reduced model, as the p-
value of hemin from the univariate analyses was 0.02 and this was thought to be clinically 
important. The reduced model accounted for 22.9% of the variability observed in these 
scores.
The only significant predictors of depression scores were a medical history of anxiety 
(β=5.36, p-value=0.003), and frequency of symptoms (Chronic vs. Sporadic β=6.88, p-
value=0.004; Recurrent vs. Sporadic β=4.71, p-value=0.007). This model only accounted for 
12.8% of the variability.
Significant predictors of physical function scores were a medical history of anxiety (β=3.97, 
p-value=0.03), frequency of symptoms (Chronic vs. Sporadic β=−5.95, p-value=0.01; 
Recurrent vs. Sporadic β=−4.65, p-value=0.007)), hemin use (β=−3.78, p-value=0.03), and a 
history of neuropathy (β=−9.10, p-value=0.001). The final reduced model including only 
these variables accounted for 23.6% of variability.
Significant predictors of fatigue scores in the final model were only frequency of symptoms 
(Chronic vs. Sporadic β=9.65, p-value=0.0003; Recurrent vs. Sporadic β=5.66, p-
value=0.003). The initial model accounted for 20.0% of the variability observed in these 
scores. In a reduced model including only frequency of symptoms and a history of 
neuropathy (which was significant in the initial model), the explained variability dropped to 
just 12.8%. In the final reduced model, adding back in neuropathy, anxiety, gender, and PBG 
level increased the explained variability to 16.5% (Table 3).
There were no significant predictors of anxiety scores. A medical history of anxiety was not 
included in the initial model as it is redundant. This model only accounted for 3.4% of the 
variability in these scores. No reduced model was selected due to this poor model fit.
The only significant predictor of sleep disturbance scores was frequency of symptoms 
(Chronic vs. Sporadic β=7.18, p-value=0.002; Recurrent vs. Sporadic β=5.35, p-
value=0.002). A history of anxiety was also included in the reduced model as this was felt to 
be clinically relevant and the p-value in the initial model was 0.07. The reduced model 
accounts for only 9.8% of the variability in these scores.
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Significant predictors of satisfaction with social roles scores were frequency of symptoms 
(Recurrent vs. Sporadic β=−5.20, p-value=0.02), hemin use (β=−4.84, p-value=0.02), a 
medical history of anxiety (β=−5.99, p-value=0.009), and a history of neuropathy (β=−7.80, 
p-value=0.05). The reduced model accounted for 18.3% of the variability in satisfaction with 
social roles scores.
Genotype-PROMIS Associations
Associations between HMBS genotype and PROMIS domain scores were explored. There 
were no significant differences between patients harboring different mutation classes 
(missense, nonsense, splice site, or insertion/deletion mutations) in any of the domains 
whether symptomatic or asymptomatic.
DISCUSSION
AIP is a rare genetic disorder of heme biosynthesis with variable clinical severity; few 
studies have evaluated disease impact on QoL or determined what measureable domains best 
capture their QoL. A small focus group study, primarily in patients with recurrent attacks, 
found that patients experience substantial feelings of isolation due to the diagnosis itself as 
well as its symptoms31. Stress is a possible precipitator of symptoms and many patients 
struggle with chronic fatigue31. A more recent qualitative interview study found significant 
disease burden in patients with many reporting chronic symptoms, specifically pain. Of note, 
this study was conducted in patients with recurrent acute attacks and therefore represents the 
most severe end of the disease spectrum32. Here, we assessed the PROMIS-57 scale in a 
more diverse, well characterized group of AIP patients, from asymptomatic to severely 
affected (Table 1).
Sample characteristics were similar to those previously described13. All domains had a large 
proportion of patients with clinically significant impairment lending support to these 
domains being important in capturing QoL for AIP patients. While depression scores were 
not significantly different from the general population, it is often observed in patients with 
severe AIP. Depression is likely still an important domain to measure, especially in patients 
who develop recurrent attacks, despite it not being observed more frequently than in the 
general population in our sample.
All the PROMIS domains were able to discriminate well between asymptomatic and 
symptomatic patients with symptomatic patients having significantly worse scores in every 
domain. This illustrates that all the PROMIS domains are sensitive to the disease. Many 
important clinical variables were significantly associated with domain scores in the 
univariate analyses, showing responsiveness of the PROMIS scales.
Postmenopausal women with AIP are generally thought to be less severely affected than 
premenopausal women8,33; however, menopause was not a significant variable in any of the 
PROMIS domains It is possible that this cohort included more severely affected patients, 
regardless of menopausal status, or that symptoms of menopause itself obfuscate the results. 
Alternatively, the sample size of postmenopausal women (40 patients) may have been too 
small to detect a difference.
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In the multiple regression models, the variables that were most frequently significant as 
predictors of PROMIS domain scores were symptom frequency, hemin use, and medical 
histories of neuropathy, anxiety, and/or nausea at baseline. Most of the models explained 
~20% of the variability observed in the domain scores. The anxiety model did not have any 
significant predictors. This was surprising, as clinically one would expect patients with more 
frequent symptoms and indicators of more severe disease (neuropathy, chronic nausea, etc.) 
to be more anxious. Anxiety is commonly seen in AIP patients as previously reported21. In 
the present study, we observed that anxiety scores were significantly worse than those in the 
general population and symptomatic patients had significantly worse scores than 
asymptomatic patients which is consistent with previous reports. Therefore, it is possible 
that anxiety is not directly related to disease severity but rather just a general feature of 
symptomatic patients.
In addition to anxiety, the sleep disturbance model also did not have many clinical features 
associated with the domain. Disturbances in circadian rhythms of AIP patients has been 
previously shown34 and the recently completed EXPLORE study also showed that many 
patients with recurrent attacks experience tiredness. Further assessments are needed to 
determine whether sleep disturbance is a critical domain to be measured when assessing 
QoL in AIP. It is clear that sleep disturbance is an issue in AIP both clinically and from these 
data; however, it remains to be elucidated whether it is an issue that stems from other 
primary domains (pain interference, anxiety, etc.).
The EXPLORE study also showed that the three domains most affected for AHP patients 
with recurrent attacks were pain and discomfort, anxiety and depression, and ability to 
perform usual activities as determined by the EQ-5D-5L tool35. However, these findings do 
not address the issue of which domains are affected primarily and which are secondary to 
the others.
Overall, both the clinical and biochemical variables were not as useful in predicting the 
domain scores as it was hoped they would be. While the clinical predictors explained some 
of the variability observed in PROMIS domain scores, there was much variability left 
unexplained, and some models were poor. One possibility is that other disease features 
should be assessed, such as opiate use and/or presence of chronic pain (separate from 
chronic neuropathy). In addition, the categorization of the data should be reassessed. Some 
of the predictors may be stronger if broken out individually, for example frequency of hemin 
use.
While the sample size in this study was limited, this is the largest study of QoL in AIP to 
date. The main limitations of this study were that the symptoms were all patient-reported 
and the subjects were predominantly Caucasian and female. Therefore, the results cannot be 
generalized to other groups, including other ethnicities, and potentially other countries as 
this population only included US patients. However, most symptomatic AIP patients are 
female; thus, the demographics of the study population were similar to the AIP patient 
population as a whole. Given that the symptom categories were patient-reported there may 
be some mis-categorization, specifically between the recurrent and chronic groups. Another 
limitation may have been that the recall of all the PROMIS domains covered the past seven 
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days with the exception of the physical function domain which did not specify a time period. 
It is possible that a longer recall period may be more appropriate in AIP patients. Symptoms 
can be quite variable especially across the disease severity spectrum and a longer recall 
period may allow for a more comprehensive picture of how the disease affects patients’ 
QoL. Additionally, urine PBG levels were recorded in varying units and needed to be 
transformed which may have affected the results.
CONCLUSIONS
All PROMIS domains (anxiety, depression, pain interference, fatigue, sleep disturbance, 
physical function, and satisfaction with social roles) were able to discriminate well between 
symptomatic and asymptomatic patients with AIP. The pain interference, anxiety, and 
fatigue domains were most associated with the clinical features assessed in symptomatic 
patients. These domains are consistent with what is observed in clinical practice. The sleep 
disturbance items should be further assessed to determine if they are relevant to this 
population as a separate domain. Additional longitudinal modeling to assess whether 
individual patient variations in PBG/ALA measurements and symptoms over time are 
associated with PROMIS score changes as well as assessing whether PROMIS can capture 
changes in QoL due to treatment response are needed to improve on this QoL study in AIP. 
Our results demonstrate that the PROMIS domains are sensitive to many of the key clinical 
variables noted in AIP patients and that these domains are important to accurately measure 
QoL in this group.
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Figure 1. 
This figure shows box-plots illustrating the discrimination of PROMIS scores between 
symptomatic and asymptomatic AIP patients. Scores are significantly worse in each domain 
for symptomatic patients.
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Figure 2. 
This figure shows box-plots illustrating the differences in PROMIS domain scores for the 
different severity categories of AIP patients. Scores are significantly worse in each domain 
for increasingly symptomatic patients, with the exception of anxiety scores.
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Table 1-
Characteristics of Patient Population
Characteristics N (%)
Gender
  Female 213 (82.2%)
  Male 46 (17.8%)
Race
  White 231 (89.2%)
  Asian 9 (3.5%)
  Black 5 (1.9%)
  Native American 2 (0.8%)
  Multiple 5 (1.9%)
  Unknown 7 (2.7%)
Age at Enrollment Mean 42.9, SD 15.5 (range 18-78)
Reported Symptoms
  Yes 195 (75.3%)
  No (Latent Patients) 57 (22.0%)
  Missing 6 (2.3%)
Symptomatic Patients
Age (years) at Onset of Symptoms (N=178) Mean 25.0, SD 10.8 (range 11-66)
Number of Life Time Hospitalizations (N=195)
  0 32 (16.4%)
  1-3 67 (34.3%)
  4-6 33 (16.9%)
  7-9 7 (3.6%)
  ≥10 35 (17.9%)
  Unsure/Missing 21 (10.7%)
Frequency of Acute Attacks (N=195)
  Sporadic Acute Attacks 62 (31.8%)
  Recurrent Attacks (≥4/year) 88 (45.1%)
  Chronic Symptoms 29 (14.9)
  Other 10 (5.1%)
  Missing 6 (3.1%)
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Table 2-
PROMIS Domain Scores
Domains
Score
Patients with
Impairment* N (%) P-value
ǂ
N Mean SD
Range
Min Max
Pain Interference 229 55.1 11.3 40.7 77.0 92 (40.2) <0.0001
Depression 231 50.9 10.3 38.2 78.1 50 (21.6) 0.18
Physical Function 232 46.4 10.5 20.3 59.2 73 (31.5) <0.0001
Fatigue 231 55.7 11.4 33.1 77.7 86 (37.2) <0.0001
Anxiety 230 54.9 11.3 37.1 82.8 77 (33.5) <0.0001
Sleep Disturbance 231 53.6 10.6 30.5 77.5 65 (28.1) <0.0001
Satisfaction with Social Roles 221 47.2 12.1 26.9 66.1 64 (29.0) 0.0007
*
Impairment defined as scores >1 SD or 10 units from the population mean
ǂ
P-values from one-sample t test comparing observed sample mean with the general population mean of 50.
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Table 3-
Models Predicting PROMIS Domain Scores
Variable β Estimate 95% Confidence Limits P-value
Pain Interference
Chronic vs. Sporadic Symptoms 7.27 2.07 12.46 0.007
Recurrent vs. Sporadic Symptoms 7.24 3.37 11.11 0.0003
Panhematin Use 2.95 −0.77 6.68 0.12
Neuropathy 6.27 0.08 12.45 0.05
Nausea 5.24 0.98 9.50 0.02
*N=140, R-square=0.229
Depression
Anxiety 5.36 1.86 8.85 0.003
Chronic vs. Sporadic Symptoms 6.88 2.27 11.49 0.004
Recurrent vs. Sporadic Symptoms 4.71 1.34 8.09 0.007
*N=164, R-square=0.128
Physical Function
Chronic vs. Sporadic Symptoms −5.95 −10.52 −1.37 0.01
Recurrent vs. Sporadic Symptoms −4.65 −8.00 −1.30 0.007
Panhematin Use −3.78 −7.08 −0.47 0.03
Neuropathy −9.10 −14.67 −3.54 0.001
Anxiety −3.97 −7.50 −0.43 0.03
*N=142, R-square=0.236
Fatigue
Male 2.92 −2.01 7.85 0.2
Anxiety 2.10 −1.76 5.96 0.3
Neuropathy 5.47 −0.73 11.68 0.08
Chronic vs. Sporadic Symptoms 9.65 4.55 14.74 0.0003
Recurrent vs. Sporadic Symptoms 5.66 1.92 9.40 0.003
PBG Level 0.02 −0.01 0.05 0.2
*N=158, R-square=0.165
Anxiety
Chronic vs. Sporadic Symptoms 4.34 −0.81 9.49 0.1
Recurrent vs. Sporadic Symptoms 2.01 −1.98 5.99 0.3
Male 2.23 −2.94 7.41 0.4
Age at Onset −0.08 −0.24 0.08 0.3
*N=156, R-square=0.034
Sleep Disturbance
Anxiety 2.71 −0.78 6.19 0.1
Chronic vs. Sporadic Symptoms 7.18 2.59 11.78 0.002
Recurrent vs. Sporadic Symptoms 5.35 1.99 8.71 0.002
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Variable β Estimate 95% Confidence Limits P-value
*N=164, R-square=0.098
Satisfaction with Social Roles
Chronic vs. Sporadic Symptoms −5.04 −10.92 0.85 0.1
Recurrent vs. Sporadic Symptoms −5.20 −9.40 −1.00 0.02
Panhematin Use −4.84 −8.98 −0.70 0.02
Neuropathy −7.80 −15.58 −0.02 0.05
Anxiety −5.99 −10.46 −1.53 0.009
*N=136, R-square=0.183
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